Início › Mieloma Múltiplo › Missouri
Ensaios clínicos de Mieloma Múltiplo em Missouri
27 estudos para Mieloma Múltiplo estão buscando participantes em locais em Missouri.
Cidades em Missouri
Texto oficial do estudo (Inglês)
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Washington University School Of Medicine, St Louis
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07589634A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Washington University School of Medicine, St Louis
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT04973605A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- MidAmerica Cancer Care, Kansas City
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Washington University School Of Medicine, St Louis
RecrutandoFase 4
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05201781A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Washington University School Of Medicine, St Louis
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT04634552A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, St Louis
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07073547Collection of Tissue Samples for Cancer Research
- Washington University - St. Louis, St Louis
RecrutandoEstudo observacional
2 Months · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT00900198Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Washington University School of Medicine, St Louis
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06297226A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Washington University School of Medicine, St Louis
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06980480A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, St Louis
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 27 de ago. de 2026 · NCT07681596A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Bridgeton
- GSK Investigational Site, Springfield
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT07227311MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Belton
- MIVA Medical, Independence
- Kansas City VA Medical Center, Kansas City
- e mais 1
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- e mais 19
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, St Louis
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 14 de ago. de 2026 · NCT07764978A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Washington University/Siteman Cancer Center, St Louis
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT07284758Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
- Washington University School of Medicine, St Louis
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT06483100Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
- Washington University School of Medicine, St Louis
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 21 de jul. de 2026 · NCT07200089Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
- Washington University School of Medicine, St Louis
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 14 de jul. de 2026 · NCT06340646Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
- Washington University School of Medicine, St Louis
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 9 de jul. de 2026 · NCT06185751Integrated Cancer Repository for Cancer Research
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- e mais 3
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 19 a 110 · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT0201269964Cu-LLP2A for Imaging Hematologic Malignancies
- Washington University School of Medicine, St Louis
RecrutandoFase 1 inicialVoluntários saudáveis bem-vindos
Idades 18 e acima · Todos os sexos · Atualizado em 17 de jun. de 2026 · NCT06636175Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Louis Cancer and Breast Institute-Ballwin, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- e mais 21
RecrutandoFase 3
Todas as idades · Todos os sexos · Atualizado em 10 de jun. de 2026 · NCT05561387Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
- Washington University School of Medicine, St Louis
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 8 de jun. de 2026 · NCT07200102An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
- Washington University School of Medicine, St Louis
Recrutando
Idades de 18 a 99 · Todos os sexos · Atualizado em 1 de jun. de 2026 · NCT07226934Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Washington University /ID# 266972, St Louis
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 12 de mai. de 2026 · NCT06896916Post-Op Pain Control for Prophylactic Intramedullary Nailing.
- Saint Louis University, St Louis
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de abr. de 2026 · NCT03823534Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
- Washington University School of Medicine, St Louis
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 11 de mar. de 2026 · NCT06623630Fonte: ClinicalTrials.gov, dados obtidos em 2 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.